Skip to content
HowShorted

UroGen Pharma Ltd. short interest in 2020

In 2020, UroGen Pharma Ltd.'s disclosed short interest ran from 10.08% of shares outstanding on 15 Jan 2020 to 12.18% on 31 Dec 2020, a change of +2.10 percentage points. The year's high was 14.55% on 15 Sep 2020 and its low 10.08% on 15 Jan 2020, averaging 12.54% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 38.23 days on 31 Jul 2020. Full history: UroGen Pharma Ltd..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for UroGen Pharma Ltd. in 2020

2020 in figures

Start of year
10.08% (15 Jan 2020)
End of year
12.18% (31 Dec 2020)
Change
+2.10 pp
High
14.55% (15 Sep 2020)
Low
10.08% (15 Jan 2020)
Average
12.54%
Highest days to cover
38.23 (31 Jul 2020)
SEC filings marked
6

Every report in 2020

UroGen Pharma Ltd. short interest in 2020
SettlementShort interestDays to coverFilings since previous
15 Jan 202010.08%15.37
31 Jan 202011.44%12.59
14 Feb 202011.33%27.37
28 Feb 202011.49%17.14
13 Mar 202010.14%9.6510-K filed
31 Mar 202011.04%9.96
15 Apr 202012.19%10.98
30 Apr 202012.57%6.19
15 May 202012.39%12.1410-Q filed
29 May 202012.62%17.91
15 Jun 202012.25%15.46
30 Jun 202012.91%18.19
15 Jul 202013.62%24.93
31 Jul 202013.93%38.23
14 Aug 202014.23%19.9510-Q filed, results (8-K)
31 Aug 202014.12%18.13
15 Sep 202014.55%20.27
30 Sep 202014.46%21.29
15 Oct 202014.19%34.45
30 Oct 202013.68%34.25
13 Nov 202012.04%20.2510-Q filed, results (8-K)
30 Nov 202012.38%22.39
15 Dec 202011.18%16.91
31 Dec 202012.18%12.15

See also: UroGen Pharma Ltd.'s full history · most shorted US stocks of 2020 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.